MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.25
0.00
0.00%
Closed 16:00 05/20 EDT
OPEN
5.24
PREV CLOSE
5.25
HIGH
5.80
LOW
5.17
VOLUME
15.43K
TURNOVER
47.37K
52 WEEK HIGH
7.41
52 WEEK LOW
3.660
MARKET CAP
70.40M
P/E (TTM)
-37.2340
1D
5D
1M
3M
1Y
5Y
Merrimack Pharmaceuticals GAAP EPS of -$0.01
Merrimack Pharmaceuticals press release (NASDAQ:MACK): Q1 GAAP EPS of -$0.01. “During the first quarter of 2022 we continued to see reductions in our operating expenses and were able to close
Seekingalpha · 05/05 20:49
BRIEF-Merrimack Reports First Quarter 2022 Financial Results
reuters.com · 05/05 20:37
Merrimack Pharmaceuticals reports FY results
Merrimack Pharmaceuticals press release (NASDAQ:MACK): FY GAAP EPS of -$0.18. As of December 31, 2021, Merrimack had cash and cash equivalents and investments of $14.2 million, compared to $14.0 million
Seekingalpha · 03/09 22:17
Insider Buying: The Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Co-Founder & Independent Director Just Bought 63% More Shares
Even if it's not a huge purchase, we think it was good to see that Ulrik Nielsen, the Co-Founder & Independent Director...
Simply Wall St. · 01/27 09:48
Vaccinex, BiondVax lead healthcare gainers; Cortexyme, Mainz Biomed among losers
Gainers: Vaccinex (NASDAQ:VCNX) +19%. BiondVax Pharmaceuticals (NASDAQ:BVXV) +12%. ObsEva (NASDAQ:OBSV) +11%. Vyant Bio (NASDAQ:VYNT) +10%. Merrimack Pharmaceuticals (NASDAQ:MACK) +9%. Losers: Cortexyme (NASDAQ:CRTX) -28%. Mainz Biomed (NASDAQ:MYNZ) -25%. ...
Seekingalpha · 01/26 15:03
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 01/14 12:54
Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 12/06/2021 12:22
Merrimack Pharmaceuticals Q3 EPS $(0.04) Up From $(0.08) YoY
Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly losses of $(0.04) per share. This is a 50 percent increase over losses of $(0.08) per share from the same period last year.
Benzinga · 11/04/2021 22:16
More
No Data
Learn about the latest financial forecast of MACK. Analyze the recent business situations of Merrimack Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
50.00%Hold
50.00%Under-perform
0.00%Sell
Analyst Price Target
The average MACK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
High4.000
Average4.000
Low4.000
Current 5.25
EPS
Actual
Estimate
-0.66-0.49-0.33-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q4 2018
Institutional Holdings
Institutions: 65
Institutional Holdings: 9.18M
% Owned: 68.49%
Shares Outstanding: 13.41M
TypeInstitutionsShares
Increased
8
454.92K
New
4
49.07K
Decreased
11
78.91K
Sold Out
1
19.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/President/Treasurer/Director
Gary Crocker
Independent Director
Eric Andersen
Independent Director
Noah Levy
Independent Director
Ulrik Nielsen
Independent Director
Russell Ray
No Data
No Data
About MACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.